Femasys Q2 2024 revenue down 31% YoY to $221K; net loss widens to $4.7M

FEMASYS INC

2024-Q2 EPS reported -$0.38 revenue$492,624

Q2 2024 sales of $221,484, down 31% from $320,514 in Q2 2023.
Net loss of $4.68M ($0.21 per share) compared to $2.89M ($0.22 per share) a year ago.
Cash and cash equivalents $13.5M; expects to fund operations into July 2025.
Received CE Mark for four women's health products; completed U.S. commercial team build-out.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.